{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.8","value":"6830"},{"groupId":"OG001","spread":"27.2","value":"6920"},{"groupId":"OG002","spread":"24.0","value":"2380"},{"groupId":"OG003","spread":"22.4","value":"3860"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"AUC0-t was defined as the total-drug area under the concentration-time curve from time zero to time of last concentration measured.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.","id":"OG000","title":"Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function"},{"description":"Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.","id":"OG001","title":"Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function"},{"description":"Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG002","title":"Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function"},{"description":"Participants with severe hepatic function received Tablet A (selinexor 2 × 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG003","title":"Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetics (PK) analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication).","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8","title":"Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment","type":"PRIMARY","unitOfMeasure":"hour*nanograms per milliliter (h*ng/mL)"}